News Article

Optimed Medizinische Instrumente, the Germany-based specialist in minimally invasive therapy devices, is being bought by Hong Kong listed medical technology firm Zylox-Tonbridge.

The acquisition signals a major shift as the acquirer transitions into a truly multinational medical technology entity with a strengthened presence in Europe.

The definitive agreement to acquire, announced on January 16, marks a defining milestone in the Hong Kong company’s long-term commitment to expanding its footprint across European and global markets.

Under the terms of the agreement, Zylox-Tonbridge has the option to acquire the entire equity interest in Optimed from its existing shareholders in multiple steps.

For healthcare operators, this acquisition promises a more robust and diverse portfolio of vascular and endourology solutions. The integration of Optimed’s deep-rooted relationships with European clinical experts should accelerate clinical development and support more efficient product launches.

The deal also establishes a unified global platform spanning research, development, and manufacturing, with an expanded production base in Germany to ensure a reliable supply of innovative medical solutions.

Investors should note that the transaction is designed to generate significant operational synergies by combining Zylox-Tonbridge’s R&D capabilities with Optimed’s established global distribution network. The company expects this integration to elevate its competitive position and accelerate the international commercialization of its neuro-and peripheral vascular interventional products. According to the company’s recent communications, this disciplined approach to expansion is intended to support stable gross profit margins and enhance overall profitability.